.thumb.png.ea12d62fcb43a79b1d7a7a4664107cbc.png)
Entry posted by ADMIN
210 views
A Johnson & Johnson building is shown in Irvine, California, US, January, 24, 2017. REUTERS/Mike Blake/FilesThe US Food and Drug Administration (FDA) on Wednesday approved Johnson & Johnson?s Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.
The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the FDA said in a statement.
0
0 Comments
Recommended Comments
There are no comments to display.
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.